

REMARKS

Claims 1-17 and 43-59 are pending. Applicant elects Group I (claims 1-17 and 43-59) for examination on the merits. With regard to the requirement for an election of species, (A) an antibody or antigen-binding fragment thereof, (B) label displacement, (C) a radioisotope, (D) measurement of reporter gene expression, and (E) a membrane fraction from cells expressing the CCRL2 polypeptide are elected. Claims 1-17 and 43-59 read on at least one of the elected species.

Claims 18-25, 29-30 and 35-42 of non-elected Groups II-VII are canceled without prejudice or disclaimer; Applicant reserves the right to prosecute the nonelected subject matter in a divisional application.

The amendments are fully supported by the original disclosure and, thus, no new matter is added by their entry. The scope of claims 2-3, 17 and 46 is not changed by the present amendments because they are intended to correct informalities and to conform to the other claims. As such, they do not limit the original scope of claims 2-3, 17 and 46. New claims 47-59 are added to provide supplemental protection for the elected invention.

Applicant earnestly solicits an early and favorable examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /Gary R. Tanigawa/
Gary R. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100